Tolvaptan
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Tolvaptan: Renal-hepatic-pancreatic dysplasia
One-Sentence Summary
Tolvaptan is a selective vasopressin V2 receptor antagonist, originally used for syndrome of inappropriate antidiuretic hormone secretion (SIADH), nephrogenic syndrome of inappropriate antidiuresis and polycystic kidney disease. The TxGNN model predicts it may be effective for renal-hepatic-pancreatic dysplasia, supported by 20 publications (including 2 pivotal RCTs and a Cochrane systematic review) but no registered clinical trials in the data compiled for this report. This prediction is best seen as a subtype-level extension of an already established indication (ADPKD), not a new repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Renal-hepatic-pancreatic dysplasia |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 (as assigned in the data compiled; see note below) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: L1 normally requires at least two completed Phase 3 RCTs. The two pivotal tolvaptan RCTs (TEMPO 3:4 and REPRISE) were conducted in ADPKD generally, not specifically in this subtype, and no trial records were available in the data compiled. The level therefore applies to ADPKD, not to the predicted subtype specifically.
Why is This Prediction Reasonable?
Tolvaptan is a selective vasopressin V2 receptor antagonist. In polycystic kidney disease, vasopressin-driven cAMP signalling in renal tubular cells promotes cyst growth and fluid secretion. Blocking the V2 receptor lowers cAMP and slows cyst expansion. Preclinical work and the clinical literature (for example, van Gastel and Torres, 2017) support this vasopressin pathway as a disease driver.
Polycystic kidney disease is already among tolvaptan’s original indications. The predicted disease is a subtype-level variant (PKD3, with or without polycystic liver disease) of the same cystic kidney biology. The prediction is therefore mechanistically coherent, but it adds little beyond the existing ADPKD indication. Any use would remain limited to patients with rapidly progressing disease.
Detailed mechanism of action data was not available in the structured drug record, so the mechanism above comes from the repurposing rationale and the published literature.
Clinical Trial Evidence
Currently no related clinical trials registered in the data compiled for this report. The pivotal trials in the literature (TEMPO 3:4 and the later-stage ADPKD trial, REPRISE) are reported in the publications below, but their registry records were not linked to this prediction.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23121377 | 2012 | RCT | N Engl J Med | Tolvaptan in ADPKD (TEMPO 3:4); preclinical data indicated V2 antagonists inhibit cyst growth and slow kidney function decline |
| 29105594 | 2017 | RCT | N Engl J Med | Tolvaptan in later-stage ADPKD; earlier trial showed slowed kidney volume growth and eGFR decline, but more aminotransferase and bilirubin elevations |
| 39356039 | 2024 | Systematic Review | Cochrane Database Syst Rev | Interventions for preventing ADPKD progression, including disease-modifying agents |
| 40126492 | 2025 | Review | JAMA | ADPKD review: the most common inherited kidney disorder, causing 5% to 10% of kidney failure in the US and Europe |
| 41771281 | 2026 | Review | Lancet | Strong evidence base for tolvaptan as disease-modifying treatment, supporting early use in patients at high risk of kidney failure |
| 40844441 | 2025 | Review | Am J Kidney Dis | Core curriculum: total kidney volume, kidney function and genotype identify patients for disease-modifying therapy |
| 35487607 | 2022 | Review | Clin Liver Dis | Polycystic kidney/liver disease; tolvaptan can slow renal function decline and cyst growth |
| 40726372 | 2025 | Review | Curr Opin Nephrol Hypertens | Emerging therapies beyond tolvaptan, noted as the only FDA-approved therapy targeting progression |
| 33376103 | 2020 | Commentary | Clin J Am Soc Nephrol | Long-term safety of tolvaptan in ADPKD |
| 32392574 | 2021 | Review | Pediatr Res | Tolvaptan use in adolescents and young adults with rapidly progressing ADPKD |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11588X | Jinarc | Pack containing 28 tablets 30 mg and 28 tablets 90 mg (oral) | Not recorded in the data compiled |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): liver failure, cirrhosis of liver, substance abuse/dependence, active peptic ulcer disease, demyelinating disease.
- Drug interactions: 100 interactions were identified, of which the following are examples.
- Major: clarithromycin.
- Moderate: aprepitant, dexamethasone, empagliflozin, loperamide, miconazole, naltrexone, rifaximin, rolapitant and several potassium preparations (citrate, bicarbonate, chloride, gluconate).
- Minor: fidaxomicin, naloxegol, prucalopride.
- Guardrails from the repurposing assessment: hepatotoxicity monitoring with regular liver testing, aquaresis-related adverse effects (such as thirst and polyuria), and use limited to patients with rapidly progressing disease.
Label-based warnings and contraindications were not available in the data compiled. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is well established and pivotal RCTs support tolvaptan in ADPKD, so the PKD3 subtype prediction is credible. Because this is an extension of an existing indication and hepatotoxicity is a known risk, use needs structured safeguards.
To proceed, the following is needed:
- Confirmation of the TGA-approved indication text for Jinarc (ARTG 11588X), which was blank in the data compiled
- Label warnings and contraindications from the TGA PI, including liver monitoring requirements
- Subtype-specific data for PKD3 with or without polycystic liver disease, as the pivotal trials covered ADPKD broadly
- Patient selection criteria (rapidly progressing disease) and a liver safety monitoring plan
- Review of the major clarithromycin interaction and other CYP3A-related interactions in prescribing guidance
Other predictions in the list (ranks 2 to 10) are mostly scores from the TxGNN model (deep learning) with no clinical support; these scores may reflect similarities the model learned between related diseases, not biological evidence. They should remain on Hold, with Joubert syndrome with renal defect flagged only as a research question requiring preclinical evaluation, since a urinary concentrating defect in nephronophthisis may make V2 antagonism unsuitable.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.